Infection worries prompt EU review of Gilead leukemia drug

LONDON (Reuters) - European regulators have started a review into the safety of Gilead Sciences' leukemia drug Zydelig due to concerns over serious adverse events, including deaths.

http://ift.tt/1pd8cO2

from Reuters: Health News
via animenewspro